Determining the appropriate dose of warfarin that should be used in each patient is challenging, and the rate of adverse events at the beginning of therapy remains high. Testing for genetic variability related to warfarin sensitivity at the start of treatment is a promising strategy to guide dosing in clinical practice.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Epstein, R. S. et al. Warfarin genotyping reduces hospitalization rates results from the MM–WES (Medco–Mayo Warfarin Effectiveness Study). J. Am. Coll. Cardiol. 55, 2804–2812 (2010).
Willey, V. J. et al. Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting. Clin. Ther. 26, 1149–1159 (2004).
Eckman, M. H., Rosand, J., Greenberg, S. M. & Gage, B. F. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann. Intern. Med. 150, 73–83 (2009).
Caraco, Y., Blotnick, S. & Muszkat, M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin. Pharmacol. Ther. 83, 460–470 (2008).
Anderson, J. L. et al. for the Couma-Gen Investigators. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116, 2563–2570 (2007).
Hillman, M. A. et al. A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin. Med. Res. 3, 137–145 (2005).
Clarification of Optimal Anticoagulation Therapy through Genetics (COAG). ClinicalTrials.gov [online], (2010).
Genetics Informatics Trial of Warfarin to Prevent Deep Venous Thrombosis. ClinicalTrials.gov [online], (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J. L. Halperin has been a consultant for Astellas Pharma US, Bayer HealthCare, Biotronik, Boehringer Ingelheim, Daiichi Sankyo, Johnson & Johnson, Portola Pharmaceuticals, and Sanofi-Aventis. S. A. van der Zee declares no competing interests.
Rights and permissions
About this article
Cite this article
van der Zee, S., Halperin, J. Warfarin sensitivity genotyping closer to clinical practice. Nat Rev Cardiol 7, 549–550 (2010). https://doi.org/10.1038/nrcardio.2010.126
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2010.126
